The Hepatitis A Virus Cellular Receptor 2 pipeline drugs market research report outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Hepatitis A Virus Cellular Receptor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Gastrointestinal, Immunology, and Dermatology which include the indications Solid Tumor, Unspecified Cancer, Crohn’s Disease (Regional Enteritis), Celiac Disease, Rheumatoid Arthritis, Peanut Allergy, and Hidradenitis Suppurativa. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Hepatitis A Virus Cellular Receptor 2 pipeline targets constitutes close to 39 molecules. Out of which, approximately 35 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 5, 8, 5, 1, 12, and 4 respectively. Similarly, the universities portfolio in Phase II, Preclinical, and Discovery comprises 1, 2, and 1 molecule.
Hepatitis A Virus Cellular Receptor 2 overview
Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.
For a complete picture of Hepatitis A Virus Cellular Receptor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
